Telomir Pharmaceuticals, Inc. Common Stock (TELO) - Net Assets
Based on the latest financial reports, Telomir Pharmaceuticals, Inc. Common Stock (TELO) has net assets worth $4.96 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.79 Million) and total liabilities ($827.31K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check TELO goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.96 Million |
| % of Total Assets | 85.71% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 450.45 |
Telomir Pharmaceuticals, Inc. Common Stock - Net Assets Trend (2021–2025)
This chart illustrates how Telomir Pharmaceuticals, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See Telomir Pharmaceuticals, Inc. Common Sto defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Telomir Pharmaceuticals, Inc. Common Stock (2021–2025)
The table below shows the annual net assets of Telomir Pharmaceuticals, Inc. Common Stock from 2021 to 2025. For live valuation and market cap data, see Telomir Pharmaceuticals, Inc. Common Sto (TELO) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $5.91 Million | +819.60% |
| 2024-09-30 | $643.04K | -81.30% |
| 2023-09-30 | $3.44 Million | +466.83% |
| 2022-09-30 | $-937.28K | -1027.47% |
| 2021-09-30 | $-83.13K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Telomir Pharmaceuticals, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4087193200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $46.92 Million | 793.51% |
| Total Equity | $5.91 Million | 100.00% |
Telomir Pharmaceuticals, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Telomir Pharmaceuticals, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kron Telekomunikasyon Hizmetleri AS
IS:KRONT
|
$83.22 Million |
|
Han Kook Capital Co. Ltd
KQ:023760
|
$83.23 Million |
|
Zevia Pbc
NYSE:ZVIA
|
$83.24 Million |
|
PT Buana Artha Anugerah Tbk
JK:STAR
|
$83.25 Million |
|
Inpro SA
WAR:INP
|
$83.20 Million |
|
BIEN SPAREB.AS NK 34375
F:JX0
|
$83.18 Million |
|
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
|
$83.17 Million |
|
Les Docks des Pétroles d-Ambès - SA
PA:DPAM
|
$83.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Telomir Pharmaceuticals, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 643,037 to 5,913,370, a change of 5,270,333 (819.6%).
- Net loss of 10,413,205 reduced equity.
- New share issuances of 9,553,209 increased equity.
- Other factors increased equity by 6,130,329.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.41 Million | -176.1% |
| Share Issuances | $9.55 Million | +161.55% |
| Other Changes | $6.13 Million | +103.67% |
| Total Change | $- | 819.60% |
Book Value vs Market Value Analysis
This analysis compares Telomir Pharmaceuticals, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.69x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-09-30 | $0.00 | $1.25 | x |
| 2022-09-30 | $-0.03 | $1.25 | x |
| 2023-09-30 | $0.12 | $1.25 | x |
| 2024-09-30 | $0.02 | $1.25 | x |
| 2025-09-30 | $0.19 | $1.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Telomir Pharmaceuticals, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -176.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.24x
- Recent ROE (-176.10%) is above the historical average (-625.47%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-129.82K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-760.42K |
| 2023 | -380.19% | 0.00% | 0.00x | 1.39x | $-13.42 Million |
| 2024 | -2571.04% | 0.00% | 0.00x | 2.06x | $-16.60 Million |
| 2025 | -176.10% | 0.00% | 0.00x | 1.24x | $-11.00 Million |
Industry Comparison
This section compares Telomir Pharmaceuticals, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | $4.96 Million | 0.00% | 0.17x | $83.22 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Telomir Pharmaceuticals, Inc. Common Stock
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macu… Read more